Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Units (DMAAU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/11/2025: DMAAU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.95% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/11/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 |
52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Units
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was founded in 2020.
Core Business Areas
- SPAC Formation: The company's primary business is identifying and merging with a private company to bring it public.
Leadership and Structure
The leadership team typically includes executives with experience in investment banking and dealmaking. The organizational structure is typical of a SPAC, with a board of directors and a management team focused on identifying a target company.
Top Products and Market Share
Key Offerings
- Competitors: Other SPACs
- SPAC Units: Drugs Made In America Acquisition Corp. Units represent a combination of a share of common stock and a warrant to purchase additional shares. The goal is to find a target company to merge with. Market share is not applicable as the company is a SPAC.
Market Dynamics
Industry Overview
The SPAC market is highly cyclical, with periods of intense activity followed by periods of decline. SPACs offer a faster route to public markets than traditional IPOs but carry inherent risks related to finding a suitable target and executing a successful merger.
Positioning
Drugs Made In America Acquisition Corp. seeks to identify and acquire a business in the healthcare or pharmaceuticals industry. Its competitive advantage lies in its management team's expertise and network within the sector.
Total Addressable Market (TAM)
The TAM is difficult to quantify precisely, as it depends on the universe of potential target companies in the healthcare and pharmaceuticals sectors. The company aims to capture a portion of this market by successfully merging with a promising target.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Specific focus on healthcare/pharmaceuticals sector
- Potential for high returns if a successful merger is completed
Weaknesses
- Dependence on finding a suitable target company
- Limited operating history
- Potential for dilution of shareholder value
Opportunities
- Growing demand for healthcare and pharmaceutical products
- Increasing number of private companies seeking to go public
- Potential for synergies with acquired company
Threats
- Increased competition from other SPACs
- Regulatory changes in the healthcare/pharmaceuticals sector
- Economic downturn that could impact target companies
Competitors and Market Share
Key Competitors
- N/A - all SPACs can be considered competitors
Competitive Landscape
Drugs Made In America Acquisition Corp. competes with other SPACs seeking to acquire companies in the healthcare/pharmaceuticals sector. Success depends on the management team's expertise and network.
Growth Trajectory and Initiatives
Historical Growth: Drugs Made In America Acquisition Corp.'s growth is tied to its ability to find and acquire a target company. Until a merger is completed, there is limited historical growth to analyze.
Future Projections: Future growth depends on the success of the merger and the performance of the acquired company.
Recent Initiatives: Recent initiatives involve identifying and evaluating potential target companies.
Summary
Drugs Made In America Acquisition Corp. is a SPAC seeking a merger within the healthcare/pharmaceuticals space. The company's strength lies in its experienced management team, but it faces risks associated with finding a suitable target. Success hinges on executing a beneficial merger, making it a speculative investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investing in SPACs involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Units
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-01-28 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.